cytarabine has been researched along with Blast Phase in 146 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (14.38) | 18.7374 |
| 1990's | 60 (41.10) | 18.2507 |
| 2000's | 39 (26.71) | 29.6817 |
| 2010's | 22 (15.07) | 24.3611 |
| 2020's | 4 (2.74) | 2.80 |
| Authors | Studies |
|---|---|
| Almlöf, I; Calderón-Montaño, JM; Centio, A; Erkers, T; Estruch, M; Friedrich, S; Gad, H; Garnett, MJ; Göktürk, C; Helleday, T; Henriksson, M; Heshmati, Y; Höglund, A; Koolmeister, T; Lehmann, S; Nagesh Danda, A; Östling, P; Pham, TM; Rasti, A; Sandvall, T; Sanjiv, K; Scobie, M; Seashore-Ludlow, B; Struyf, N; Theilgaard-Mönch, K; Tsuber, V; Våtsveen, TK; Visnes, T; Walfridsson, J; Wallner, O; Warpman Berglund, U; Wiita, E | 1 |
| Alkhateeb, H; Badar, T; Gangat, N; Ilyas, R; Mangaonkar, A; McCullough, K; Pardanani, A; Patnaik, MM; Tefferi, A | 1 |
| Cao, J; Chen, Y; Dong, QF; Hu, JD; Li, F; Luo, LT; Sang, YQ; Wang, J; Wang, SL; Yang, T; Ye, YZ; Zhang, L; Zheng, J; Zheng, XY | 1 |
| Kong, P; Yao, H | 1 |
| Billingham, L; Brock, K; Copland, M; Siddique, S; Sirovica, M; Yap, C | 1 |
| Füreder, W; Gleixner, K; Grünberger, B; Hoermann, G; Kornauth, C; Schwarzinger, I; Sperr, WR; Thalhammer, R; Valent, P | 1 |
| Dağlı, M; Keles Oğlu, KS; Koplay, M; Paksoy, Y; Sivri, M | 1 |
| Boyerinas, B; Hyjek, EM; Price, TT; Sipkins, DA; Yesilkanal, AE; Zafrir, M | 1 |
| Abruzzo, L; Borthakur, G; Cortes, J; Faderl, S; Jabbour, E; Jorgensen, JL; Kantarjian, H; Konoplev, S; Luthra, R; O'Brien, S; Quintas-Cardama, A; Ravandi, F; Strati, P; Thomas, D | 1 |
| Cui, J; Gao, S; Han, W; Li, W; Liu, X; Su, L; Tan, Y; Yu, P | 1 |
| Deng, Z; Ding, B; Li, Y; Shi, Y; Zho, J | 1 |
| Audemard, A; Bergot, E; Chantepie, S; de la Gastine, B; Gac, AC; Reman, O; Verger, H | 1 |
| Burnett, AK; Hills, R; Lazenby, M; Zabkiewicz, J | 1 |
| Gordon, MJ; Kovacsovics, T; Loriaux, MM; Mayer, LD; Spurgeon, SE; Tardi, P; Traer, E; Tyner, JW | 1 |
| Abboud, C; Becker, M; Friedberg, J; Ifthikharuddin, J; Komrokji, RS; Liesveld, JL; Messina, P; Mulford, D; Oliva, J; Phillips, G; Walker, AR | 1 |
| Seth, R; Thavaraj, V | 1 |
| Carlton, D; Edelman, MJ; Fang, HB; Gojo, I; Nakanishi, T; Ross, DD; Sausville, EA; Shiozawa, K; Tan, M; Wang, WC | 1 |
| Ayres, M; Beck, JF; Chen, ZS; Ehninger, G; Gandhi, V; Grube, M; Guo, Y; Illmer, T; Jedlitschky, G; Köck, K; Kroemer, HK; Kruh, GD; Ritter, CA; Schaich, M; Siegmund, W | 1 |
| Cho, D; Kim, HJ; Kim, SH; Kim, TS; Lee, IK; Song, JH | 1 |
| Borthakur, G; Cortes, J; Jones, D; Kantarjian, HM; Luthra, R; Rios, MB; Verma, D; Verstovsek, S | 1 |
| Berendse, HW; Janssen, JJ; Merle, PA; Ossenkoppele, GJ; Schuurhuis, GJ | 1 |
| Bencini, S; Bosi, A; Gianfaldoni, G; Longo, G; Mannelli, F; Ponziani, V; Vannucchi, AM | 1 |
| Celentano, M; Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Riccardi, C | 1 |
| Asou, N; Horikawa, K; Kawakita, T; Mitsuya, H; Nanri, T; Nosaka, K; Takatsu, N; Tsuji, T | 1 |
| Jabbour, E; Kadia, T; Parikh, SA | 1 |
| Cho, SY; Huh, J; Jun, KR; Kim, B; Kim, HR; Kim, MJ; Lee, JN; Lee, JY; Oh, SH; Park, TS; Shin, JH; Song, SA | 1 |
| Berthou, C; Castaigne, S; Cayuela, JM; Cony-Makhoul, P; Deau, B; Gardembas, M; Guerci, A; Guilhot, F; Guilhot, J; Guyotat, D; Hayette, S; Huguet, F; Legros, L; Mahon, FX; Michallet, M; Nicolini, FE; Pautas, C; Réa, D; Rousselot, P; Weiss, IR | 1 |
| Ayemou, R; Koffi, KG; Kouakou, B; Méité, N; Nanho, DC; Ndiaye, FS; Sanogo, I; Sawadogo, GD; Sékongo, YM; Tolo-Diebkilé, A | 1 |
| Brizard, F; Canioni, D; Chomel, JC; Mayeur-Rousse, C; Randriamalala, E; Sorel, N; Turhan, AG; Voldoire, M | 1 |
| Apperley, J; Foroni, L; Ibrahim, A; Marin, D; Milojkovic, D; Reid, A | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Plunkett, W; Ravandi, F | 1 |
| Braess, J; Holdenrieder, S; Kolligs, FT; Manukyan, D; Stieber, P | 1 |
| Barraco, D; Candoni, A; Fanin, R; Pirracchio, A; Simeone, E | 1 |
| Axdorph, U; Björkholm, M; Carneskog, J; Grimfors, G; Hansen, J; Linder, O; Ljungman, P; Löfvenberg, E; Malm, C; Simonsson, B; Stenke, L; Turesson, I; Udén, AM; Vilén, L | 1 |
| Ayyildiz, O; Bolaman, Z; Demir, S; Kadiköylü, G; Köseoğlu, M; Müftüoğlu, E; Sönmez, HM | 1 |
| Bali, P; Bhalla, K; Burnette, PK; Huang, M; Jove, R; Loughran, T; Nimmanapalli, R; O'Bryan, E; Tepperberg, J | 1 |
| Borker, A; Ode, D; Yu, L | 1 |
| Abgrall, JF; Berthou, C; Braekeleer, MD; Bris, MJ; Calvez, GL; Herry, A; Marion, V; Morel, F | 1 |
| Inatomi, Y; Miyashita, T; Miyauchi, J; Shen, L; Toyama, K; U, M; Wu, Z | 1 |
| Cox, J; Johnson, L; Lickliter, JD; McHugh, G; Tan, J; Wickham, NW; Wood, F; Wood, NJ | 1 |
| Aslan, D; Cetin, M; Hiçsönmez, G; Ozyürek, E; Tuncer, AM; Unal, S; Yenicesu, I | 1 |
| Ascani, S; Bonomini, S; Caramatti, C; Colla, S; Craviotto, L; Crugnola, M; De Celis, I; Giuliani, N; Hojden, M; Morandi, F; Rizzoli, V; Sabbatini, E; Sammarelli, G | 1 |
| Bujassoum, S; Lipton, JH; Rifkind, J | 1 |
| Cros, E; Dumontet, C; Galmarini, CM; Graham, K; Mackey, JR; Thomas, X | 1 |
| Raghunadharao, D; Rajappa, S; Rao, IS; Surath, A; Uppin, SG | 1 |
| Hassan, HT; Lu, C | 1 |
| Beason, K; Hughson, M; Kozlov, I; Yu, C | 1 |
| Fiser, K; Klamová, H; Moravcová, J | 1 |
| Andreeff, M; Cortes, J; Du, M; Estrov, Z; Gandhi, V; Plunkett, W; Sampath, D; Shi, Z | 1 |
| Antonioli, E; Baccini, M; Bosi, A; Gianfaldoni, G; Leoni, F; Mannelli, F | 1 |
| Aleskog, A; Barbany, G; Bengtsson, M; Björnberg, A; Höglund, M; Larsson, R; Lindhagen, E; Olsson-Strömberg, U; Simonsson, B | 1 |
| Du, X; Ke, XY; Liu, Y; Lu, ZS; Lv, JQ; Ma, J; Shen, ZX; Xu, XH; Zeng, XY; Zhan, ZM; Zhang, XH; Zhao, YM | 1 |
| Altintas, A; Ayyildiz, O; Cil, T; Kaplan, MA; Kilinc, I | 1 |
| Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Ravandi, F; Thomas, D; Wierda, W | 1 |
| Balleisen, L; Buss, EC; Emmerich, B; Fischer, T; Fruehauf, S; Hehlmann, R; Ho, AD; Hochhaus, A; Müller, MC; Ottmann, OG; Schuld, P; Topaly, J | 1 |
| Chang, HJ; Cho, MS; Choi, MY; Kong, JH; Kwon, JM; Lee, KE; Lee, SM; Lee, SN; Mun, YC; Nam, E; Nam, SH; Seong, CM; Yoo, SH | 1 |
| Büchner, T; Creutzig, U; Döhner, H; Reinhardt, D; Sauerland, MC; Schlenk, RF; Zimmermann, M | 1 |
| Kouides, PA; Rowe, JM | 1 |
| Feldmann, L; Guerci, A; Guerci, O; Marchal, S; Merlin, JL; Missoum, N; Rose, C; Witz, F | 1 |
| Hosokawa, T; Kurashige, T; Misaki, Y; Tomoda, T; Wakiguchi, H | 1 |
| Catapano, CV; Colombo, T; Conter, V; Damia, G; Gervasoni, M; Giudici, G; Limonta, M; Liso, V; Masera, G; Specchia, G | 1 |
| Du, M; Gandhi, V; Kantarjian, HM; Plunkett, W | 1 |
| Belloc, F; Bernard, P; Boiron, JM; Cony-Makhoul, P; Dumain, P; Lacombe, F; Laurent, G; Marit, G; Puntous, M; Reiffers, J | 1 |
| Ambrosetti, A; Aprili, F; Krampera, M; Martinelli, G; Meneghini, V; Perona, G; Pizzolo, G; Veneri, D | 1 |
| Bauduer, F; Blanc, MC; Cadiou, M; Delmas-Marsalet, B; Delmer, A; Marie, JP; Rio, B; Zittoun, R | 1 |
| Björkholm, M; Gruber, A; Liliemark, EK; Liliemark, J; Peterson, C; Pettersson, B | 1 |
| Baker, M; Bhalla, K; Grant, S | 1 |
| Harbott, J; Lampert, F; Li, L; Lohmeyer, J; Pralle, H; Ritterbach, J; Schroyens, W | 1 |
| Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P | 1 |
| Cortes-Franco, J; Estey, E; Kornblau, SM | 1 |
| Akerman, S; Allen, SL; Barile, B; Budman, DR; DeMarco, LC; Kreis, W; Marsh, JH; Schulman, P; Schuster, MW | 1 |
| Grande, M | 1 |
| Dunphy, CH; Kitchen, S; Saravia, O; Velasquez, WS | 1 |
| Heinemann, V; Jehn, U; Pötscher, C | 1 |
| Mark, HF; Medeiros, LJ; Miranda, RN; Rintels, P; Wu, CD | 1 |
| Nakamura, T; Ueda, T; Yamauchi, T | 1 |
| Amadori, S; Fazi, P; Mandelli, F; Montefusco, E; Petti, MC; Picardi, A; Testi, AM | 1 |
| Hedley, DW; McCulloch, EA | 1 |
| Kaya, H; Kobayashi, K; Matano, S; Nakamura, S; Sugimoto, T; Yoshida, T | 1 |
| Jowitt, SN; Yin, JA | 1 |
| Amabile, M; Arpinati, M; Farabegoli, P; Martinelli, G; Testoni, N; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL; Zuffa, E | 1 |
| Hagiwara, S; Miwa, A; Nagai, M; Soda, Y; Takaku, F; Takezako, N; Togawa, A; Yuo, A | 1 |
| Ahmed, T; Darzynkiewicz, Z; Feldman, EJ; Halicka, HD; Lake, D; Seiter, K; Traganos, F | 1 |
| Baccarani, M; Damiani, D; Manfroi, S; Michelutti, A; Ottaviani, E; Russo, D; Tosi, P; Tura, S; Visani, G | 1 |
| Capria, S; Mandelli, F; Meloni, G; Modena, V; Vignetti, M | 1 |
| Goi, K; Iijima, K; Inukai, T; Kagami, K; Kinoshita, A; Kojika, S; Mori, T; Nakazawa, S; O-Koyama, T; Sugita, K; Suzuki, T; Tezuka, T | 1 |
| Du, M; Estey, E; Gandhi, V; Keating, MJ; Nowak, B; Plunkett, W | 1 |
| Aulitzky, W; Huber, C; Peschel, C; Schneller, F; Schuler, M; Schumacher, K; Thaler, J | 1 |
| Hayashi, S; Inatomi, Y; Iwama, H; Katagiri, T; Kawakubo, K; Kuriyama, Y; Miyazawa, K; Nehashi, Y; Ohyashiki, K; Shimamoto, T; Shyohji, N; Toyama, K; Uchida, Y; Yaguchi, M | 1 |
| Chiba, S; Hirai, H; Honda, H; Kanda, Y; Yazaki, Y | 1 |
| Balkham, SE; Elgie, AW; Sargent, JM; Taylor, CG; Williamson, CJ | 1 |
| Frost, BM; Larsson, R; Liliemark, E; Lönnerholm, G; Nygren, P; Peterson, C | 1 |
| Diehl, V; Dimski, T; Lathan, B; Pantke, B; Schinköthe, T; Staib, P; Voliotis, D; Wiedenmann, S | 1 |
| Elgie, AW; Sargent, JM; Taylor, CG; Williamson, CJ | 1 |
| Chimishkian, K; Gurova, K; Litvinova, E; Mentkevich, G | 1 |
| Hokland, P; Kristensen, JS; Nørgaard, JM; Olesen, G; Pedersen, B | 1 |
| Estey, E; Feldman, EJ; Kantarjian, HM; Keating, M; Koller, CA; O'Brien, S; Rios, MB | 1 |
| Braess, J; Hiddemann, W; Kern, W; Pförtner, J; Schleyer, E | 1 |
| Frost, BM; Gustafsson, G; Larsson, R; Lönnerholm, G; Nygren, P | 1 |
| Copia, C; Ferrara, F; Leoni, P; Mele, G; Montillo, M; Morra, E; Nosari, A; Tedeschi, A | 1 |
| Druker, BJ; Kolibaba, KS; Ohno-Jones, S; Thiesing, JT | 1 |
| Boos, J; Creutzig, U; Feldges, A; Gadner, H; Hermann, J; Kühl, J; Niemeyer, CM; Ritter, J; Sawatzki, DB; Schwabe, D; Selle, B; Zimmermann, M | 1 |
| Baer, MR; Barone, S; Block, AW; Lawrence, D; Sait, SN; Wetzler, M | 1 |
| Erikson, C; Florschütz, A; Rosahl, W; Schreiber, J; Schumann, HJ; Zugehör, M | 1 |
| Andreeff, M; Chang, S; Estrov, Z; Gribble, G; Harris, D; Honda, T; Jackson, CE; Konopleva, M; Leysath, CE; May, WS; Munsell, M; Ruvolo, P; Sporn, MB; Stiouf, I; Suh, N; Tsao, T; Zhao, S | 1 |
| Albitar, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; O'Brien, S; Resta, D; Rios, MB; Shan, J; Talpaz, M; Thomas, DA | 1 |
| McCulloch, EA; Yang, GS | 1 |
| Imai, Y; Nagata, K; Nara, N; Shiina, S; Suzuki, T; Tanikawa, S; Tohda, S; Tomiyama, J | 1 |
| Arakawa, M; Chou, T; Hayashi, N; Wakabayashi, M | 1 |
| Abakumov, EM; Isaev, VG; Khoroshko, ND; Navashin, SM; Savchenko, VG; Sokolov, AN; Turkina, AG; Viadro, MM | 1 |
| Brunner, K; Dear, KB; Haurani, F; Holland, JF; Karanas, A; Silver, RT; Weil, M | 1 |
| Chan, TK; Chiu, E; Liang, R; Todd, D | 1 |
| Büchner, T; Busemann, C; Hiddemann, W; Kiehl, M; Schleyer, E; Wörmann, B; Zühlsdorf, M | 1 |
| Tanaka, M | 1 |
| Chen, GJ; Imai, Y; Murohashi, I; Nagata, K; Nara, N; Shiina, S; Suzuki, T; Tanikawa, S; Tohda, S; Tomiyama, J | 1 |
| Beran, M; Deisseroth, A; Estey, EH; Gutterman, J; Kantarjian, HM; Keating, MJ; Kontoyiannis, D; O'Brien, S; Rios, MB; Talpaz, M | 1 |
| Arlin, Z; Bhalla, K; Grant, S; Holladay, C; Ibrado, AM; Jasiok, M | 1 |
| McCulloch, EA; Minden, MD; Minkin, S; Wang, C; Yang, GS | 1 |
| Beran, M; Estey, EH; Freireich, EJ; Gutterman, J; Kantarjian, HM; Keating, MJ; McCredie, KB; O'Brien, S; Talpaz, M | 1 |
| Capizzi, RL; White, JC | 1 |
| Gonzales-Chambers, R; Przepiorka, D | 1 |
| Arthur, KA; Dhawan, RK; Kufe, DW; Mayer, RJ; Spriggs, DR; Stone, RM | 1 |
| Gattringer, C; Konwalinka, G; Linkesch, W; Thaler, J | 1 |
| Derigs, G; Heyll, A | 1 |
| Andreeff, M; Hegewisch-Becker, S; Tafuri, A | 1 |
| Frydecka, I; Kotlerek-Haus, S; Kuliczkowski, K; Nowicka, J; Sedek, K | 1 |
| Canellos, GP | 1 |
| Cannistra, SA; Griffin, JD; Groshek, P | 1 |
| Ganser, A; Hoelzer, D; Ottmann, OG; Schulz, G | 1 |
| Chiba, S; Kikuchi, M; Misago, M; Mori, N; Nagata, K; Nakata, K; Oda, S; Otani, H; Sato, T; Tsukada, J | 1 |
| Arthur, DC; Brunning, RD; Michels, SD; Robison, LL; Saumur, J | 1 |
| Frydecka, I; Harłozińska, A; Kuliczkowski, K; Noworolska, A; Sedek, K | 1 |
| Miyazaki, T; Morioka, M; Sakurada, K | 1 |
| Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, SJ; Kolitz, J; Raymond, V; Young, CW | 1 |
| Cavelli, F; Degnan, TJ; Holland, JF; Mick, R; Silver, RT | 1 |
| Fu, Z; Hou, CH; Li, JL; You, XY; Zhang, ZY; Zhu, YF | 1 |
| Fujiwara, Y; Murase, T; Nagai, H; Nakaide, Y; Ohkita, T; Tanaka, M | 1 |
| Andersson, B; Beran, M; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Talpaz, M; Walters, RS | 1 |
| Heinemann, V; Meyn, RE; Murray, D; Plunkett, W; Walters, R | 1 |
| Furukawa, Y; Inoue, T; Kishida, T; Kojima, K; Sagawa, H; Sannomiya, Y; Sasaki, A; Yamane, T; Yokomatsu, Y; Yoshikawa, T | 1 |
| Preisler, HD; Raza, A | 1 |
| Dua, H; Kochipillai, V; Kumar, L | 1 |
| Adams, TM; Estey, E; Kantarjian, H; Keating, MJ; Liliemark, JO; Nowak, B; Plunkett, W | 1 |
| Barnett, MJ; Ganesan, TS; Lister, TA; Miller, A; Richards, MA; Rohatiner, AZ | 1 |
| Franke, A; Mey, U | 1 |
| Háber, J; Klener, P; Kolesková, E | 1 |
5 review(s) available for cytarabine and Blast Phase
| Article | Year |
|---|---|
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Burkitt Lymphoma; Cytarabine; Daunorubicin; Female; Humans; Imatinib Mesylate; Immunophenotyping; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Multiple Primary; Piperazines; Pyrimidines; Remission Induction | 2004 |
Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Cytarabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Life Tables; Male; Middle Aged; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 1993 |
Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Flow Cytometry; Humans; Immunophenotyping; Male; Mercaptopurine; Methotrexate; Neoplastic Stem Cells; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Primary Myelofibrosis; Remission Induction; Vincristine | 1996 |
Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Etoposide; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Methotrexate; Mitoxantrone; Remission Induction; Time; Treatment Outcome | 1999 |
Treatment of chronic granulocytic leukemia in blastic crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Blood Transfusion; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Splenectomy | 1989 |
26 trial(s) available for cytarabine and Blast Phase
| Article | Year |
|---|---|
Implementing the EffTox dose-finding design in the Matchpoint trial.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Blast Crisis; Cytarabine; Humans; Idarubicin; Imidazoles; Models, Statistical; Outcome Assessment, Health Care; Pyridazines; Research Design; Vidarabine | 2017 |
Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells.
Topics: Adolescent; Adult; Antigens, CD34; Antigens, CD7; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Cell Count; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Harringtonines; Hematologic Diseases; Homoharringtonine; Humans; Immunophenotyping; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Mitoxantrone; Myeloid Cells; Neoplastic Stem Cells; Remission Induction; Young Adult | 2014 |
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Cladribine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Time Factors | 2008 |
Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival.
Topics: Adult; Aged; ATP-Binding Cassette Transporters; Blast Crisis; Cell Membrane; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; LLC-PK1 Cells; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stem Cells; Survival Rate | 2009 |
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Exanthema; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Prospective Studies; Pyrimidines; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Gemtuzumab; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Vidarabine; Young Adult | 2012 |
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Statistics, Nonparametric; Stem Cell Transplantation; Survival Rate | 2002 |
Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Cell Cycle; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Cytarabine; DNA Damage; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid, Acute; Middle Aged; Oncogene Protein v-akt; Pharmacokinetics; Phosphorylation; Pilot Projects; Protein Kinases; Salvage Therapy; Staurosporine; Tumor Cells, Cultured | 2006 |
[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cyclophosphamide; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mucositis; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Treatment Outcome; Vincristine | 2006 |
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Etoposide; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome | 2007 |
Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.
Topics: Adult; Aged; Blast Crisis; Cytarabine; Deoxycytidine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia | 1993 |
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Chemical and Drug Induced Liver Injury; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1993 |
Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged | 1995 |
A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Carboplatin; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Blast Crisis; Cell Cycle; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; In Vitro Techniques; Infusions, Intravenous; Kinetics; Leukemia, Myeloid, Acute; Pilot Projects; Vidarabine | 1995 |
Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Survival Rate | 1998 |
Prognosis in adult AML is precisely predicted by the DISC-assay using the chemosensitivity-index Ci.
Topics: Adult; Aminoglutethimide; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cell Survival; Cytarabine; Danazol; Drug Screening Assays, Antitumor; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Predictive Value of Tests; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Analysis; Tamoxifen; Vidarabine | 1999 |
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Salvage Therapy; Treatment Outcome; Vidarabine | 1999 |
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Treatment Outcome | 2001 |
High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Cytogenetic Analysis; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Remission Induction; Survival Rate; Treatment Outcome | 2001 |
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Blood Cell Count; Cytarabine; Cytogenetic Analysis; Enzyme Inhibitors; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Survival Rate; Treatment Outcome | 2002 |
[Experience with using aclarubicin in the treatment of acute leukemia and blast crisis of chronic myeloid leukemia].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction | 1992 |
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytarabine and lomustine. A Cancer and Leukemia Group B study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Busulfan; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lomustine; Male; Middle Aged; Remission Induction; Time Factors | 1992 |
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1989 |
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytosine arabinoside and cis-chloronitrosurea during the course of busulfan-maintained remission.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Busulfan; Clinical Trials as Topic; Cytarabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lomustine; Male; Middle Aged; Random Allocation; Sex Factors | 1988 |
115 other study(ies) available for cytarabine and Blast Phase
| Article | Year |
|---|---|
MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Cell Proliferation; Cytarabine; DNA Repair Enzymes; Doxorubicin; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Mitosis; Neoplastic Stem Cells; Phosphoric Monoester Hydrolases; Prognosis; Pyrimidines; Reactive Oxygen Species; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases.
Topics: Blast Crisis; Cytarabine; Daunorubicin; Humans; Mutation; Myeloproliferative Disorders | 2023 |
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Forkhead Transcription Factors; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; RNA, Messenger; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2023 |
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cladribine; Cytarabine; Dendritic Cells; Doxorubicin; Hematologic Neoplasms; Humans; Male; Prognosis; Remission Induction; Salvage Therapy | 2020 |
Major response of PNH to an AML chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Cytarabine; Daunorubicin; Hemoglobinuria, Paroxysmal; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 2018 |
An atypical isolated CNS blast crisis in chronic myeloid leukaemia.
Topics: Aged; Antineoplastic Agents; Blast Crisis; Brain; Central Nervous System Diseases; Cytarabine; Glucocorticoids; Humans; Image Enhancement; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Maintenance Chemotherapy; Male; Methotrexate; Neuroimaging; Spinal Cord; Treatment Outcome | 2018 |
Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy.
Topics: Adult; Animals; Antibodies, Neutralizing; Antimetabolites, Antineoplastic; Blast Crisis; Bone Marrow; Cell Adhesion; Child; Child, Preschool; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Ki-67 Antigen; Male; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasm, Residual; Osteoblasts; Osteopontin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction; Transplantation, Heterologous; Tumor Microenvironment | 2013 |
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Vincristine | 2014 |
The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Immunophenotyping; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult | 2014 |
[Dasatinib-related pneumonia? An example of pharmacovigilance survey].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Pharmacovigilance; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins; Thiazoles; Tomography, X-Ray Computed; Vincristine | 2015 |
The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Female; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Leukemia, Myeloid, Acute; Male; Proto-Oncogene Proteins c-akt; Triazoles | 2015 |
CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Inhibitory Concentration 50; Liposomes; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 2017 |
Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Blood Cell Count; Central Nervous System Neoplasms; Chemoprevention; Child; Clinical Protocols; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Imatinib Mesylate; Injections, Spinal; Methotrexate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction | 2008 |
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cell Survival; Cytarabine; Drug Evaluation, Preclinical; Drug Synergism; Etoposide; G1 Phase; Humans; Hydroxamic Acids; Leukemia, Myeloid; S Phase; Tumor Cells, Cultured; Vorinostat | 2009 |
Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Blast Crisis; Blotting, Western; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Matrix Metalloproteinase 2; Middle Aged; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Young Adult | 2009 |
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Vincristine | 2009 |
A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.
Topics: Antineoplastic Agents; Aphasia; Ataxia; Benzamides; Blast Crisis; Confusion; Cytarabine; Diagnosis, Differential; Hearing Loss; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2009 |
Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Female; Genes, Wilms Tumor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Predictive Value of Tests; Survival Rate; Time Factors; Transcription, Genetic; Treatment Outcome; WT1 Proteins; Young Adult | 2010 |
Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
Extramedullary tumors presenting double vision in patients with t(8;21)(q22;q22) acute myeloid leukemia lacking mutations in the receptor tyrosine kinase genes KIT or FLT3.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Blast Crisis; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Diplopia; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Paranasal Sinus Neoplasms; Proto-Oncogene Proteins c-kit; Stem Cell Transplantation; Translocation, Genetic; Transplantation, Homologous | 2010 |
Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Core Binding Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine | 2010 |
Acute myeloid leukemia associated with t(10;17)(p13-15;q12-21) and phagocytic activity by leukemic blasts: a clinical study and review of the literature.
Topics: Adolescent; Adult; Antigens, CD; Antimetabolites, Antineoplastic; Blast Crisis; Child; Chromosome Mapping; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 17; Cytarabine; Daunorubicin; Female; Humans; Leukemia; Magnetic Resonance Imaging; Male; Middle Aged; Peroxidase; Phagocytes; Translocation, Genetic | 2010 |
[Therapeutic impact of alpha interferon in chronic myelogenous leukaemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Remission Induction; Retrospective Studies; Socioeconomic Factors; Virus Activation; Young Adult | 2010 |
Unique association of systemic mastocytosis and myeloid/lymphoid neoplasm in blast crisis with abnormality of FGFR1 gene.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA-Binding Proteins; Fatal Outcome; Gene Rearrangement; Humans; Idarubicin; Male; Mastocytosis, Systemic; Myeloproliferative Disorders; Receptor, Fibroblast Growth Factor, Type 1; Transcription Factors | 2012 |
Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dasatinib; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Thiazoles; Treatment Outcome; Vidarabine | 2012 |
Nature and dynamics of nucleosome release from neoplastic and non-neoplastic cells.
Topics: Apoptosis; Blast Crisis; Cytarabine; Etoposide; Hep G2 Cells; Humans; L-Lactate Dehydrogenase; Leukemia; Neoplasms; Neutrophils; Nucleosomes; Tetradecanoylphorbol Acetate; TNF-Related Apoptosis-Inducing Ligand | 2012 |
Hypopyon as the first sign of relapse in acute lymphoblastic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cyclophosphamide; Cytarabine; Doxorubicin; Eye Neoplasms; Fatal Outcome; Female; Humans; Mercaptopurine; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vincristine | 2013 |
Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Topics: Benzamides; Benzoquinones; Blast Crisis; Cytarabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidines; Rifabutin; src-Family Kinases; STAT5 Transcription Factor; Trans-Activators | 2002 |
Blast crisis of chronic myeloid leukemia: diagnosis prompted by T(8;9).
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Child, Preschool; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cytarabine; Daunorubicin; Ethmoid Sinus; Etoposide; Fusion Proteins, bcr-abl; Humans; Karyotyping; Leukemia, Myeloid, Accelerated Phase; Male; Meninges; Mitoxantrone; Remission Induction; Sacrococcygeal Region; Sarcoma, Myeloid; Thioguanine; Translocation, Genetic | 2002 |
Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Topics: Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosome Aberrations; Chromosome Painting; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fatal Outcome; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Autologous | 2003 |
Effects of TNFalpha on the growth and sensitivity to cytosine arabinoside of blast progenitors in acute myelogenous leukemia with special reference to the role of NF-kappaB.
Topics: Adult; Aged; Blast Crisis; Cell Division; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; NF-kappa B; Tumor Necrosis Factor-alpha | 2003 |
HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death.
Topics: Apoptosis; Benzopyrans; Blast Crisis; Bone Marrow Cells; Cell Death; Cell Survival; Cytarabine; Drug Synergism; Enzyme Inhibitors; Genes, bcl-2; Hematopoietic Stem Cells; Humans; Leukemia; Lymphoma; Nitriles; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2003 |
Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Cells; CD13 Antigens; Child; Child, Preschool; Cytarabine; Female; Humans; Leukemia, Myeloid; Leukemic Infiltration; Lipopolysaccharide Receptors; Male; Methylprednisolone; Mitoxantrone; Prognosis; Remission Induction; Survival Rate; Thioguanine; Treatment Outcome | 2004 |
Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction | 2004 |
5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Blast Crisis; Cytarabine; Humans; Leukemia, Myeloid; Molecular Sequence Data; Nucleotidases; Prognosis; RNA, Messenger | 2004 |
Isolated central nervous system blast crisis in chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Humans; Hydrocortisone; Imatinib Mesylate; Injections, Spinal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Meninges; Methotrexate; Neoplasm Invasiveness; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction | 2004 |
Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Biomarkers, Tumor; Blast Crisis; Cell Line, Tumor; Chromosome Aberrations; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Pilot Projects; Receptors, Cytokine; Stem Cell Factor; Treatment Outcome | 2006 |
CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity.
Topics: Acute Disease; Adult; Antigens, CD; B-Lymphocytes; Blast Crisis; Bone Marrow Cells; CD79 Antigens; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Flow Cytometry; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Male; T-Lymphocytes; Translocation, Genetic | 2005 |
Gene expression profiles of two accelerations in a CML patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mitoxantrone; Multigene Family; Oligonucleotide Array Sequence Analysis; Vidarabine | 2006 |
Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Pilot Projects; Prognosis; Remission Induction | 2006 |
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Cytarabine; Daunorubicin; Feasibility Studies; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; In Vitro Techniques; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Vincristine | 2006 |
Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Blood-Brain Barrier; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Methotrexate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma, Myeloid; Treatment Outcome | 2007 |
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Pyrimidines; Survival Rate; Treatment Outcome | 2007 |
Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bile Ducts; Blast Crisis; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Cytarabine; Drug Eruptions; Hepatocytes; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Function Tests; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2007 |
Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Topics: Adolescent; Adult; Aging; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Prognosis; Risk Factors; Survival Analysis; Treatment Outcome | 2008 |
A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged | 1995 |
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Blood Cell Count; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Female; Flow Cytometry; Gene Expression; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Prognosis; Prospective Studies; Quinine; Remission Induction; Risk; Salvage Therapy; Treatment Outcome | 1995 |
Marked increase of peripheral blood myeloblasts following G-CSF therapy in a patient with acute lymphoblastic leukemia.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1995 |
Cytotoxic activity and mechanism of action of 5-Aza-2'-deoxycytidine in human CML cells.
Topics: Antineoplastic Agents; Azacitidine; Blast Crisis; Cytarabine; Decitabine; DNA, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Time Factors; Tumor Cells, Cultured | 1993 |
Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia.
Topics: Arabinofuranosylcytosine Triphosphate; Blast Crisis; Cytarabine; Deoxycytosine Nucleotides; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tumor Cells, Cultured | 1994 |
Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Cell Cycle; Cytarabine; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Recurrence; Treatment Outcome | 1993 |
Early lymphoid blastic crisis following major karyotypic conversion in a chronic myeloid leukemia patient treated with interferon-alpha.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Child; Cytarabine; Daunorubicin; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Prednisone; Recombinant Proteins; Remission Induction; Vincristine | 1994 |
In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Blood Proteins; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Protein Binding; Serum Albumin; Topoisomerase II Inhibitors | 1993 |
Blastic phase chronic myeloid leukemia with a four-break rearrangement: t(11;9)(9;22)(q23;p22q34;q11).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Chromosome Banding; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Daunorubicin; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Translocation, Genetic; Vincristine | 1993 |
Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Nervous System Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1993 |
Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Carboplatin; Cytarabine; Drug Resistance; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Tetrahydrouridine; Treatment Outcome | 1993 |
Central nervous system granulocytic sarcoma in a patient with essential thrombocythemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blast Crisis; Bone Marrow; Busulfan; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Epidural Space; Fatal Outcome; Frontal Bone; Humans; Leukemia, Myeloid; Leukemic Infiltration; Male; Methylprednisolone; Spinal Canal; Thrombocythemia, Essential | 1996 |
Chronic myeloid leukemia manifested during megakaryoblastic crisis.
Topics: Adult; Antimetabolites, Antineoplastic; Blast Crisis; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Fatal Outcome; Humans; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 1996 |
A new sensitive method for determination of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo.
Topics: Alkaline Phosphatase; Arabinofuranosylcytosine Triphosphate; Blast Crisis; Cell Line; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Radioimmunoassay; Sensitivity and Specificity; Tumor Cells, Cultured | 1996 |
Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blast Crisis; Calcium; Cell Membrane; Cytarabine; Flow Cytometry; Glutathione; Humans; Leukemia, Myeloid, Acute; Lipid Peroxidation; Neoplastic Stem Cells; Oxidation-Reduction; Oxidative Stress; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1996 |
[Low-dose combination cytarabine and etoposide for myeloid crisis transformed from unclassified chronic myeloproliferative disorder].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Chronic Disease; Cytarabine; Drug Administration Schedule; Etoposide; Humans; Male; Middle Aged; Myeloproliferative Disorders | 1996 |
Clonality switch in acute myeloid leukemia.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Clone Cells; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Dosage Compensation, Genetic; Female; Hematopoiesis; Heterozygote; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Prednisolone; Remission Induction; Thioguanine; Vincristine | 1996 |
FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Bone Marrow Transplantation; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine | 1996 |
[Successful treatment of acute non-lymphoblastic leukemia from myelodysplastic syndrome by combination of human macrophage colony-stimulating factor (M-CSF) and low dose cytosine arabinoside: M-CSF-induced proliferation and tyrosine phosphorylation in leu
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blast Crisis; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Macrophage Colony-Stimulating Factor; Myelodysplastic Syndromes; Phosphorylation; Tyrosine | 1996 |
Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Camptothecin; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Topotecan | 1997 |
Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors.
Topics: Adult; Antineoplastic Agents, Phytogenic; Apoptosis; Blast Crisis; Bone Marrow; Bone Marrow Cells; Cell Division; Cell Survival; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Female; Harringtonines; Hematopoietic Stem Cells; Homoharringtonine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 1997 |
Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Blast Crisis; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lupus Erythematosus, Systemic; Methotrexate; Prednisone; Remission Induction; Transplantation, Autologous; Vincristine | 1997 |
Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Blast Crisis; Cell Division; Cell Line; Chromosome Mapping; Chromosomes, Human, Pair 11; Cytarabine; DNA Replication; Etoposide; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Immunophenotyping; Infant; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Granulocyte Colony-Stimulating Factor; Tumor Cells, Cultured | 1998 |
[Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Clone Cells; Cytarabine; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Survivors | 1998 |
Comparison of BCL-2 and BAX protein expression with in vitro sensitivity to ARA-C and 6TG in AML.
Topics: Apoptosis; bcl-2-Associated X Protein; Blast Crisis; Bone Marrow Cells; Cytarabine; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Thioguanine | 1999 |
In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia.
Topics: Amsacrine; Antineoplastic Agents; Blast Crisis; Bone Marrow; Cell Survival; Child; Cytarabine; Doxorubicin; Drug Screening Assays, Antitumor; Erythrocytes; Etoposide; Humans; Leukemia, Myeloid, Acute; Recurrence; Scandinavian and Nordic Countries; Thioguanine | 1999 |
Aphidicolin markedly increases the in vitro sensitivity to ara-C of blast cells from patients with AML.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aphidicolin; Blast Crisis; Bone Marrow Cells; Cell Survival; Cytarabine; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1999 |
Effects of CSFS and their combinations with chemotherapeutic agents (CH) on leukemic blasts (LB) in children (MTT-assay).
Topics: Adolescent; Adult; Antineoplastic Agents; Blast Crisis; Bone Marrow Cells; Child; Child, Preschool; Colony-Stimulating Factors; Cytarabine; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1999 |
Leukaemia cell drug resistance and prognostic factors in AML.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Blast Crisis; Child; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Prognosis; Tetrazolium Salts | 1999 |
Cytidine deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells.
Topics: Acute Disease; Blast Crisis; Bone Marrow Cells; Cell Count; Cytarabine; Cytidine Deaminase; Deamination; Humans; Leukemia, Myeloid; Tumor Cells, Cultured | 1999 |
Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?
Topics: Antineoplastic Agents; Blast Crisis; Cell Survival; Child; Cytarabine; Dexamethasone; Down Syndrome; Doxorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thioguanine; Treatment Outcome; Tumor Cells, Cultured | 2000 |
Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Vidarabine | 2000 |
Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cell Division; Cell Survival; Cytarabine; Daunorubicin; Fusion Proteins, bcr-abl; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; Interleukin-3; Leukemia, Megakaryoblastic, Acute; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcr; Pyrimidines; Stem Cell Factor; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
[Primary pulmonary manifestation of extramedullary acute myelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bronchoalveolar Lavage Fluid; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Middle Aged; Prednisolone; Radiography; Thioguanine; Vincristine | 2001 |
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.
Topics: Annexin A5; Apoptosis; bcl-2-Associated X Protein; Blast Crisis; Caspase 3; Caspases; Cell Differentiation; Cell Survival; Cytarabine; DNA Fragmentation; Drug Interactions; Flow Cytometry; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Membrane Potentials; Mitogen-Activated Protein Kinases; Oleanolic Acid; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Retinoids; Tretinoin; Tumor Cells, Cultured | 2002 |
A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Blast Crisis; Cell Survival; Cytarabine; Humans; Leukemia, Myeloid; Tumor Cells, Cultured | 1992 |
Comparison of the proliferative activity and sensitivity to cytosine arabinoside of leukemic blast progenitors in acute myeloblastic leukemia at diagnosis and in relapse.
Topics: Blast Crisis; Cell Division; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Recurrence; Tumor Cells, Cultured | 1992 |
[Treatment of CML with blastic crisis by the combination therapy of VP and low-dose Ara-C].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Prednisolone; Vincristine | 1992 |
Non-aggressive therapy for chronic myeloid leukaemia in blastic transformation.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Hydroxyurea; Leukemia; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Remission Induction; Thioguanine; Vincristine | 1992 |
Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Blast Crisis; Cytarabine; DNA, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; S Phase; Tumor Stem Cell Assay | 1992 |
Enhancement of the cytotoxicity of cytosine arabinoside by interleukin-3.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Blast Crisis; Cytarabine; Drug Synergism; Feasibility Studies; Humans; Interleukin-1; Interleukin-3; Leukemia, Myeloid; Tumor Stem Cell Assay | 1992 |
The in vitro growth patterns and drug sensitivities of leukemic blast progenitors among the subtypes of acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Blast Crisis; Cell Division; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Stem Cells | 1992 |
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Diseases; Cytarabine; Daunorubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Middle Aged; Prognosis; Remission Induction; Survival Analysis | 1992 |
Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Blast Crisis; Bone Marrow Cells; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Kinetics; Leukemia, Myeloid; Monocytes; Recombinant Proteins; Reference Values; Stem Cells; Tumor Cells, Cultured | 1991 |
Hydrocortisone in culture protects the blast cells in acute myeloblastic leukemia from the lethal effects of cytosine arabinoside.
Topics: Blast Crisis; Cell Survival; Cytarabine; DNA; Dose-Response Relationship, Drug; Doxorubicin; Humans; Hydrocortisone; Leukemia, Myeloid, Acute; Thymidine; Time Factors; Tritium; Tumor Cells, Cultured | 1991 |
Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Drug Resistance; Female; Follow-Up Studies; Humans; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pilot Projects; Prednisone; Survival Rate; Vincristine | 1991 |
A critical role for uridine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-beta-D-arabinofuranosylcytosine phosphorylation in human leukemia cells.
Topics: Blast Crisis; Cytarabine; Deoxycytidine Kinase; Humans; Kinetics; Leukemia; Phosphorylation; Ribonucleotides; Tumor Cells, Cultured; Uracil Nucleotides | 1991 |
Acute tumor lysis syndrome in a patient with chronic myelogenous leukemia in blast crisis: role of high-dose Ara-C.
Topics: Acute Disease; Adult; Blast Crisis; Bone Marrow Transplantation; Cytarabine; Dose-Response Relationship, Drug; Graft vs Host Disease; Humans; Kidney Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Tumor Lysis Syndrome | 1990 |
A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia.
Topics: Adult; Blast Crisis; Cytarabine; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Leukemia; Male; Middle Aged | 1990 |
Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Austria; Blast Crisis; Cytarabine; Drug Evaluation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1990 |
Chronic myelomonocytic leukemia: clinical data, morphological features, and outcome in 56 patients.
Topics: Biomarkers, Tumor; Blast Crisis; Bone Marrow; Cytarabine; Germany, West; Hemorrhage; Humans; Leukemia; Leukemia, Myelomonocytic, Chronic; Life Tables; Prednisone; Splenomegaly; Survival Rate | 1990 |
Colony-stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside.
Topics: Adult; Blast Crisis; Cell Cycle; Child; Colony-Stimulating Factors; Cytarabine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Interleukin-4; Leukemia, Myeloid; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Tumor Cells, Cultured | 1990 |
Influence of small doses cytosine arabinoside (Ara-C) on leukemic cells in vitro and in vivo. Results in patients with leukemia and myelodysplastic syndrome.
Topics: Adult; Aged; Blast Crisis; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Cytarabine; Dose-Response Relationship, Drug; Female; Histocytochemistry; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes | 1986 |
Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia.
Topics: Blast Crisis; Cell Division; Colony-Stimulating Factors; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Interphase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1989 |
Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine arabinoside in patients with myelodysplastic syndrome. A pilot study.
Topics: Adult; Aged; Blast Crisis; Bone Marrow; Colony-Stimulating Factors; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins | 1989 |
[Successful treatment with a small dose of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in a case of chronic myelomonocytic leukemia in blastic crisis].
Topics: Antineoplastic Agents; Blast Crisis; Cytarabine; Female; Humans; Leukemia, Myelomonocytic, Chronic; Middle Aged; Remission Induction | 1989 |
Refractory anemia with excess of blasts in transformation hematologic and clinical study of 52 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Bone Marrow Transplantation; Chromosome Aberrations; Chromosome Disorders; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Female; Humans; Karyotyping; Male; Middle Aged; Remission Induction | 1989 |
Study of differentiation of fresh human leukemic cells by low dose cytosine arabinoside (LD Ara-C) and 12-O-tetradecanoylphorbol-13-acetate (TPA).
Topics: Antigens, Neoplasm; Blast Crisis; Bone Marrow; Cell Adhesion Molecules; Cell Differentiation; Cytarabine; Glycoproteins; Humans; Leukemia; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1989 |
[Therapy of the preleukemic state: effect of androgens on refractory anemia].
Topics: Adult; Aged; Androgens; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Blast Crisis; Cholecalciferol; Chromosome Aberrations; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Preleukemia; Prognosis | 1988 |
Curative effect of harringtonine semisynthetic harringtonine and HOAP on nonlymphocytic leukemias. Analysis of 304 cases.
Topics: Adult; Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Harringtonines; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Vincristine | 1987 |
[Acute leukemia subsequent to sideroblastic anemia: response to low dose cytosine arabinoside].
Topics: Adult; Anemia, Sideroblastic; Blast Crisis; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute | 1988 |
Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction | 1988 |
Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA Damage; DNA, Neoplasm; Drug Synergism; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone | 1988 |
[Differentiating effect of the oral administration of vitamin D and vitamin A in acute myelocytic leukemia after BHAC-DMP therapy].
Topics: Administration, Oral; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Vitamin A; Vitamin D | 1988 |
Proto-oncogene transcript levels and acute nonlymphocytic leukemia.
Topics: Acute Disease; Blast Crisis; Bone Marrow; Cell Differentiation; Cell Division; Cytarabine; Gene Expression Regulation; Histones; Humans; Leukemia; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogenes; RNA, Neoplasm; Triose-Phosphate Isomerase | 1987 |
Low dose cytosar in the treatment of chronic granulocytic leukaemia--blast crisis.
Topics: Adult; Blast Crisis; Cytarabine; Female; Humans; Leukemia, Myeloid | 1987 |
Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Metabolic Clearance Rate | 1987 |
A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults.
Topics: Acute Disease; Adult; Aged; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Middle Aged; Time Factors | 1987 |
Low-dose Ara-C treatment in elderly patients with acute myeloblastic leukemia.
Topics: Aged; Blast Crisis; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1987 |
[High doses of cytosine arabinoside in the treatment of refractory leukemia].
Topics: Blast Crisis; Cytarabine; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute | 1987 |